The initial pubic offering of Temasek and Motilal Oswal Private Equity-backed Molbio Diagnostics opens today at a price band of Rs 768-807 a share. The ₹939.70-crore IPO closes on Wednesday.Up to 50% of the net offer is reserved for Qualified Institutional Buyers (QIBs), while retail investors can bid up to 35 per cent and non-institutional investors 15 per cent. It has reserved a little over 20,500 shares for its employees, who receive a discount of ₹76 per share.Investors can bid in a lot size of 18 sharesThe Goa-based company’s IPO comprises a fresh issue of up to Rs 200 crore and an offer for sale (OFS) of up to 91.66 lakh equity shares by existing shareholders, valued at Rs 739.70 crore. Under the OFS, Exxora Trading LLP, Dr Chandrasekhar Bhaskaran Nair, India Business Excellence Fund III, Gopalkrishna Mangalore Kini, J Guru Dutt, Gopalakrishna Sampathgiri, Sangeetha M Kini, M A Usha Rani, M A Rohit, Shruthi G Kini and several other shareholders will divest their stakes.As part of IPO, point-of-care diagnostics company Molbio Diagnostics Ltd on Friday raised ₹281.5 crore from anchor investors by allotting 34.88 lakh shares to 33 anchor investors at ₹807 apiece. Among them were Goldman Sachs, BlackRock Global Funds, Mirae Asset, Nippon India Mutual Fund, ICICI Prudential Mutual Fund, Kotak Mutual Fund, Tata Mutual Fund, WhiteOak Capital, Bajaj Life Insurance, and HDFC Life Insurance.Domestic mutual funds received 23.54 lakh shares, accounting for 67.51 per cent of the anchor book through 19 schemes of nine fund houses, the company said in a disclosure to the stock exchanges.From the net issue, the company proposes to utilise ₹106 crore towards capital expenditure for setting up infrastructure for an R&D facility, Centre of Excellence and connected office space, ₹72 crore towards the purchase of plant, machinery and other equipment for its Goa Unit I, Goa Unit II and Visakhapatnam unit, while the remaining funds will be used for general corporate purposes.